Key result
Apixaban shows consistent efficacy and safety in AF patients with comorbidities across ARISTOTLE subanalyses.
Why the study?
Does apixaban demonstrate efficacy and safety in patients with atrial fibrillation and various comorbidities?
Does apixaban demonstrate efficacy and safety in patients with atrial fibrillation and various comorbidities?
This review highlights the efficacy and safety of apixaban in patients with atrial fibrillation and complex comorbidities based on ARISTOTLE trial subanalyses.
The article discusses the choice of anticoagulant therapy in patients with atrial fibrillation and a number of concomitant diseases – coronary heart disease, including after percutaneous coronary interventions, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, and in the elderly. The data of subanalyses of a randomized clinical trial of ARISTOTLE are presented, indicating a high profile of efficacy and safety of the new oral anticoagulant apixaban in this category of patients.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2018) conducted a review in Atrial fibrillation with comorbidities. Apixaban was evaluated. Apixaban demonstrated a high profile of efficacy and safety in patients with atrial fibrillation and various comorbidities based on subanalyses of the ARISTOTLE trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: